The company is a leader in Alzheimer's research and has developed the world's first drug for the treatment of moderate to severe stages of the disease. It also offers drugs for Parkinson's, depression, and dystonia. Merz Therapeutics aims to address the unique needs of patients with movement disorders and other health conditions that severely impact their quality of life. The company has a patient-centric approach, cutting-edge research and development efforts, and dedicated commercial teams. Merz Therapeutics is headquartered in Frankfurt am Main, Germany, and represented in over 90 countries, with a North America affiliate based in Raleigh, North Carolina. It is part of the Merz Group, a family-owned company that has been developing innovations to serve unmet patient and customer needs for over 110 years.